EUVIMEDEUVIMED entdecken
Crossref

German Real-World Risk of Recurrence for HR-Positive, HER2-Negative Early Breast Cancer

A Nusch, D Reschke, J Schröder, C Iuliano, C Pfister, K Ringwald, L Kruggel, K Gratzke

Senologie - Zeitschrift für Mammadiagnostik und -therapie · 01.05.2026 · 23 (02) · e27-e28

DOI: 10.1055/s-0046-1819795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Senologie - Zeitschrift für Mammadiagnostik und -therapie, erschienen am 01.05.2026. Verfasst von A Nusch und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Describing invasive disease-free survival (iDFS) for patients with HR+/HER2- early breast cancer (eBC) recruited in the German tumor registry breast cancer (TMK). Methodology: TMK is an open, multicenter clinical registry. From 2007–2014, 2,250 patients were enrolled at over 140 sites at the start of (neo)adjuvant therapy, with follow-up up to 10 years. iDFS was measured from start of systemic therapy to local recurrence, distant metastasis, or death. This analysis presents unadjusted real-world data for 1,123 patients with HR+/HER2- eBC (stage I–III).

Results

Across the TMK cohort, 3-year iDFS rate was 92.5% (95% CI: 90.6%–94.0%), and declined to 64.6% (95% CI: 57.6%–70.8%) at 10 years. Among patients meeting NATALEE trial inclusion criteria, the 3-year iDFS rate was 91.1% (95% CI: 88.4%–93.2%), decreasing to 58.5% (95% CI: 49.7%–66.3%) at 10 years. Patients not meeting NATALEE criteria demonstrated a higher 3-year iDFS rate of 96.5% (95% CI: 93.4%–98.2%) and a 10-year iDFS rate of 76.1% (95% CI: 60.6%–86.2%). iDFS rates were lower for stage II compared to stage III. In the TMK cohort, 89.6% of patients received neoadjuvant or adjuvant chemotherapy; with rates being higher in the NATALEE cohort (96.8%) than in non-NATALEE (73.2%).

Conclusion

Even with increased chemotherapy, high-risk patients per NATALEE criteria show lower long-term iDFS, underlining the need for improved treatment options in this patient population. The introduction of CDKi in combination with endocrine therapy may offer additional long-term benefit (referring to NATALEE 5 year data). Publication History Article published online: 19 May 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Nusch, A., Reschke, D., Schröder, J., Iuliano, C., Pfister, C., Ringwald, K., Kruggel, L., & Gratzke, K. (2026). German Real-World Risk of Recurrence for HR-Positive, HER2-Negative Early Breast Cancer. Senologie - Zeitschrift für Mammadiagnostik und -therapie, 23(02), e27-e28. https://doi.org/10.1055/s-0046-1819795

Vancouver

Nusch A, Reschke D, Schröder J, Iuliano C, Pfister C, Ringwald K, et al. German Real-World Risk of Recurrence for HR-Positive, HER2-Negative Early Breast Cancer. Senologie - Zeitschrift für Mammadiagnostik und -therapie. 2026;23(02):e27-e28. doi:10.1055/s-0046-1819795

BibTeX
@article{Nusch2026,
  author = {Nusch, A and Reschke, D and Schröder, J and Iuliano, C and Pfister, C and Ringwald, K and Kruggel, L and Gratzke, K},
  title = {German Real-World Risk of Recurrence for HR-Positive, HER2-Negative Early Breast Cancer},
  journal = {Senologie - Zeitschrift für Mammadiagnostik und -therapie},
  year = {2026},
  volume = {23},
  number = {02},
  pages = {e27--e28},
  doi = {10.1055/s-0046-1819795}
}
Kostenlos starten →